SCHEMBL1493484

SCHEMBL1493484

Cc1cccc(-n2nnnc2S)c1C

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
TSHR P16473 4/20 0.46
P2RX7 Q99572 4/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KCNN4 O15554 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
ADRB1 P08588 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
ALOX15 P16050 1/20 0.36
OPRM1 P35372 1/20 0.36
HSD11B1 P28845 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8653708 0.86 ALDH1A1 (0.40) ALDH1A1TSHRP2RX7HTTLMNA
SCHEMBL11638648 0.86 ALDH1A1 (0.62) ALDH1A1TSHRP2RX7HTTLMNA
SCHEMBL1493508 0.83 KCNN4 (0.44) ALDH1A1TSHRKCNN4
SCHEMBL1493409 0.80 ALDH1A1 (0.56) ALDH1A1TSHRHTTLMNANPSR1
SCHEMBL28299784 0.77 ALDH1A1 (0.79) ALDH1A1TSHRHTTLMNAKCNN4
SCHEMBL28879265 0.76 ALDH1A1 (0.38) ALDH1A1TSHRP2RX7HTTLMNA
SCHEMBL1537920 0.74 ALDH1A1 (0.43) ALDH1A1TSHRP2RX7LMNANPSR1
SCHEMBL1493493 0.73 ALDH1A1 (0.47) ALDH1A1TSHRP2RX7HTTLMNA
SCHEMBL1493503 0.72 ALDH1A1 (0.54) ALDH1A1TSHRHTTLMNANPSR1
SCHEMBL1493397 0.72 P2RX7 (0.52) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102056920-A Tetrazole compounds as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD 2011-05-11 CN disclosed
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-04-14 US disclosed
EP-2288603-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2011-03-02 EP disclosed
WO-2009150614-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-12-17 WO disclosed
EP-0657297-B2 Security document having a transparent or translucent support and containing interference pigments. AGFA GEVAERT (BE) 2003-04-23 EP disclosed
US-6284350-B1 HAVING VISUAL PERSONIFIED MARK OF THE OWNER AGFA-GEVAERT (BE) 2001-09-04 US disclosed
US-6250554-B1 Chip card comprising an imaged-receiving layer AGFA-GEVAERT (BE) 2001-06-26 US disclosed
US-6210777-B1 Security document having a transparent or translucent support and containing interference pigments AGFA-GEVAERT (BE) 2001-04-03 US disclosed
EP-1033258-A1 Security document consisting of a laminate AGFA-GEVAERT N.V. (BE) 2000-09-06 EP disclosed
EP-0977083-A1 An optical card comprising an imaged layer AGFA-GEVAERT N.V. (BE) 2000-02-02 EP disclosed
EP-0557616-A1 A silver halide material suitable for use in a silver salt diffusion transfer process AGFA-GEVAERT N.V. (BE) 1993-09-01 EP disclosed
EP-0554930-A1 A silver halide material suitable for use in a silver salt diffusion transfer process AGFA-GEVAERT N.V. (BE) 1993-08-11 EP disclosed
EP-0546599-A1 An image receiving material for use in the silver salt diffusion transfer process AGFA-GEVAERT N.V. (BE) 1993-06-16 EP disclosed
EP-0546598-A1 Image receiving layer for use in a silver salt diffusion transfer process AGFA-GEVAERT N.V. (BE) 1993-06-16 EP disclosed
US-5204212-A Phosphate-free; development nuclei in receiving layer AGFA-GEVAERT, N.V. (BE) 1993-04-20 US disclosed
EP-0527521-A1 A silver halide photographic material AGFA-GEVAERT N.V. (BE) 1993-02-17 EP disclosed
US-5162192-A Methylethanolamines AGFA-GEVAERT, N.V. (BE) 1992-11-10 US disclosed
EP-0496126-A1 A processing liquid for the silver salt diffusion transfer process AGFA-GEVAERT N.V. (BE) 1992-07-29 EP disclosed
EP-0398435-A1 Liquid for DTR-photography AGFA-GEVAERT N.V. (BE) 1990-11-22 EP disclosed
EP-0397926-A1 Processing liquid for use in silver halide photography AGFA-GEVAERT N.V. (BE) 1990-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R ALDH1A1 3233/4885TSHR 44/4885P2RX7 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.